Therapeutic Asset Ratings

Gotistobart

her2bbζ/cd19t+ t cells

Immunoglobulin G1-kappa, anti-[Homo sapiens CLDN18 (SFTPJ, surfactant associated protein J) isoform 2, extracellular domain 1 (EC1)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-448) [VH (Homo sapiens IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (92.9%) L123>T (113), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01 (100%), G1m17,1 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448)], (221-220')-disulfide with kappa light chain humanized (1'-220') [VKAPPA (Homo sapiens IGKV4-1*01 (91.1%) - IGKJ4*01 (100%), CDR-IMGT [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (159), V101 (197) (114'-220')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1 lacking the glutamine synthetase (GS-KO) gene, glycoform alfa

Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific

IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER

Inbrx-106

Mcla-158

Mdna11

mdx2001

mt-4561

neo212

ngm707

Osimertinib

Petosemtamab

Precemtabart Tocentecan

q702

Regorafenib

Satricabtagene Autoleucel

Solnerstotug

Tak-500

Tcr-T Cells

TESTOSTERONE UNDECYLATE

th9619

Tocilizumab

tt-4